BRAF-Targeted Therapy to Treat Superior Vena Cava Syndrome in a Patient With Metastatic Cancer.
University of California, Irvine, Irvine, CA.
Shane M
SM
Mesko
The Angeles Clinic and Research Institute, Los Angeles, CA k.jean.rose@gmail.com.
Katherine J
KJ
Rosenthal
The Angeles Clinic and Research Institute, Los Angeles, CA.
Peter D
PD
Boasberg
The Angeles Clinic and Research Institute, Los Angeles, CA.
Omid
O
Hamid
D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D006801:Humans; D007211:Indoles / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D008207:Lymphatic Metastasis; D008297:Male; D008545:Melanoma / Q000235:genetics / Q000556:secondary*; D058990:Molecular Targeted Therapy / Q000379:methods; D009154:Mutation; D048493:Proto-Oncogene Proteins B-raf / Q000037:antagonists & inhibitors* / Q000235:genetics; D012878:Skin Neoplasms / Q000235:genetics / Q000473:pathology*; D013449:Sulfonamides / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D013479:Superior Vena Cava Syndrome / Q000188:drug therapy / Q000209:etiology* / Q000378:metabolism; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome; D000077484:Vemurafenib
D000970:Antineoplastic Agents; D007211:Indoles; D013449:Sulfonamides; D000077484:Vemurafenib; C482119:BRAF protein, human; D048493:Proto-Oncogene Proteins B-raf